Background Few studies have been performed on postrelapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy[6 months than in those with a duration B6 months. Conclusion Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
Results Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy[6 months than in those with a duration B6 months. Conclusion Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.
Introduction
Women with estrogen receptor (ER)-positive breast cancer remain at particular risk for late recurrence, which is defined as relapse more than 5 years after the initial treatment [1, 2] . Encouragingly, extended adjuvant endocrine therapy can reduce the frequency of late recurrence [3] [4] [5] [6] . Accurate and reliable estimates of the risk of recurrence after 5 years of endocrine therapy, which would enable appropriate decisions regarding extended periods of this treatment modality, are, therefore, required. The risk of long-term relapse is related to the number of positive lymph nodes and the large size of invasive tumors [7] [8] [9] [10] . Furthermore, multi-parametric molecular assays, including IHC4, OncotypeDX, EndoPredict, PAM50, and Breast Cancer Index, have been developed for predicting the early (relapse less than 5 years after the initial treatment) and/or late distant recurrence [8, 11] . Predictive factors for the early and late recurrence, especially in postmenopausal ER-positive breast cancer, have previously been reported. However, there are few studies on predictors of prognosis after relapse. We previously demonstrated that the high expression of ER, increased phosphorylation of ERa serine 167, and low expression of Ki67 and p53 in primary breast tumors were associated with response to the first-line endocrine therapy and post-relapse survival in ER-positive metastatic breast cancer [12] [13] [14] [15] . In these cases, tamoxifen was mainly used as an adjuvant endocrine therapy and/or as the first-line endocrine therapy after relapse. However, prognostic factors after relapse might differ between women who receive adjuvant tamoxifen and those who are treated with aromatase inhibitors among postmenopausal women with ERpositive metastatic breast cancer. Furthermore, post-relapse survival might differ between patients with the early or late recurrence. Recently, novel-targeting agents, such as everolimus, CDK 4/6 inhibitors, and PI3 K inhibitors, have been used in combination with the endocrine therapies in ER-positive metastatic breast cancer [16, 17] . Therefore, understanding the response to endocrine therapy and survival in metastatic ER-positive breast cancer is critical to develop appropriate treatment strategies that utilize noveltargeted agents [17] .
We recently reported a multi-institutional joint retrospective study, carried out as Scientific Research of the Japanese Breast Cancer Society, using data from ER-positive, HER2-negative breast cancer patients with the early and late distant recurrence [9] . Because all patients in the study were given their initial treatment between 2000 and 2004, almost 80 % of postmenopausal women received aromatase inhibitors as adjuvant endocrine therapy, and anthracyclins and/or taxanes were used as adjuvant or neoadjuvant chemotherapy. In this study, which is a follow-up of the initial multi-institutional joint project, we analyzed factors that were prognostic for post-relapse survival in patients with the early and late recurrence.
Patients and methods

Patients and breast cancer samples
Patients with the early and late distant recurrence of ERpositive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. They were incorporated into a multi-institutional joint study titled 'Analysis on biological characteristics and factors predicting late recurrence in breast cancer', and the project was carried out under the auspices of Scientific Research of the Japanese Breast Cancer Society [9] . The early recurrence was defined as relapse within 5 years, and late recurrence was defined as relapse more than 5 years after the initial treatment. A total of 205 patients with the early recurrence and 134 patients with the late recurrence were analyzed in this study; 18 patients with the early recurrence and 14 patients with the late recurrence in the original cohort were excluded, because information regarding the first-line treatments after relapse was lacking. Treatment regimens and periods after the recurrence and post-relapse survival were retrospectively compared between the early and late recurrence groups. The study protocol was approved by the institutional review board in all nine institutions and conformed to the guidelines of the 1996 Declaration of Helsinki.
Expression of ER, progesterone receptor (PgR), and Ki67 in primary breast tumors was centrally assessed by immunohistochemistry (IHC). HER2-positive tumors were excluded from this study [9] .
Statistical analysis
The Chi-squared test, Student's t test, and the MannWhitney U test were used to compare clinicopathological characteristics and treatments among patients with the early and late recurrence. The estimation of post-relapse survival was performed using the Kaplan-Meier methods, and differences between survival curves were assessed with the log-rank test. Univariate and multivariate analyses with the Cox proportional hazards regression models were used to identify independent prognostic factors in all patients. p values \0.05 were considered significant.
Results
Comparison of clinicopathological characteristics and treatments between patients with the early and late recurrence
We collected data from a total of 205 women with the early distant recurrence and 134 women with the late distant recurrence in ER-positive, HER2-negative breast cancer ( Table 1 ). The median disease-free intervals were 33 months (range 1-58 months) in the early recurrence cohort and 91 months (range 60-162 months) in the late recurrence cohort. Of the 43 (21 %) patients with the early recurrence who did not receive adjuvant endocrine therapy, 12 individuals received the adjuvant endocrine therapy for less than 6 months, and 4 patients relapsed before adjuvant endocrine therapy. Fifty-four women (26 %) with the early relapse and fifty-four women (40 %) with the late relapse had multiple metastatic organs at relapse (p = 0.009). In terms of metastatic sites at relapse, the proportion of lung metastases was significantly higher in patients with late relapse than in those with the early relapse (35 and 22 %, respectively, p = 0.01). The fraction of patients who received endocrine therapy for the first-line treatment after relapse was 65 % in the early recurrence cohort and 79 % in the late recurrence cohort (p = 0.03). There were no differences between the two cohorts with regard to time-toprogression with respect to the first-line endocrine therapy (median 11 months, range 1-120 months versus median 12.5 months, range 0.6-77 months, the early versus late relapse). On the other hand, total duration of endocrine therapies after relapse was significantly shorter in patients with the early recurrence compared with those with the late recurrence (median 14 months, range 0-120 months versus median 23 months, range 0-78 months, the early versus late relapse, p = 0.001). The number of chemotherapy regimens was significantly higher in patients with the early recurrence compared with those with the late recurrence (median 3, range 1-8 versus median 2, range 1-6, the early versus late relapse, p = 0.01). The median follow-up periods after relapse were 76 months (range 14-177 months) in the early recurrence cohort and 133 months (range 66-175 months) in the late recurrence cohort. Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence (p = 0.0074, Fig. 1 ). The 5-year post-relapse survivals were 35 % in patients with the early recurrence and 57 % in patients with the late recurrence.
Factors predicting post-relapse survival in patients with the early recurrence
We then analyzed factors predicting post-relapse survival in patients with the early recurrence. When analyzing post-relapse survival, setting the cut-off point at 3 years yielded the most significant difference between patient groups. KaplanMeier analysis showed that patients whose disease-free interval was more than 3 years displayed longer post-relapse survival compared with patients with shorter disease-free intervals (p = 0.007, Fig. 2 ). The 5-year post-relapse survivals were 29 % in patients with a disease-free interval B3 years and 49 % in patients with a disease-free interval [3 years. Univariate analysis (Table 2) Table 2) .
Factors predicting post-relapse survival in patients with the late recurrence
We next analyzed factors predicting post-relapse survival in patients with the late recurrence. The Kaplan-Meier analysis showed that patients who responded to first-line endocrine therapy (duration [6 months) had longer postrelapse survival compared with those on the first-line endocrine therapy for B6 months (p \ 0.0001, Fig. 3 ). Five-year post-relapse survival was 41 % in patients with a duration of the first-line endocrine therapy B6 months and 70 % in patients with a duration of the first-line endocrine therapy [6 months. The univariate analysis (Table 3) identified significant correlations between long post-relapse survival and small number of positive lymph nodes (p = 0.049), use of radiation therapy, a single metastatic organ at relapse (p = 0.002), a long duration of the first-line endocrine therapy (p \ 0.0001), and a long total duration of endocrine therapies (p = 0.04) after relapse. Multivariate analysis revealed significantly improved post-relapse survival in late recurrence patients with a single metastatic organ at relapse (p = 0.03), a long duration of the first-line endocrine therapy (p \ 0.0001), and a long total duration of endocrine therapies (p = 0.01) after relapse ( Table 3) .
Comparison of clinicopathological characteristics and treatments according to response to the first-line endocrine therapy after relapse in patients with the late recurrence
The above results indicate that the duration of the first-line endocrine therapy was the most significant prognostic factor for post-relapse survival in patients with the late recurrence. Therefore, we compared the clinicopathological characteristics and treatments between a duration of first-line endocrine therapy B6 and [6 months in patients who were treated endocrine therapy as the initial treatment at relapse (Table 4) . ER expression in primary breast tumors was significantly higher in patients with a duration of the first-line endocrine therapy [6 months than in those with a duration B6 months (p = 0.03). The mean percentage of ER-positive cells was 66.0 % in patients with a duration of the first-line endocrine therapy [6 months, and 51.6 % in those with a duration B6 months (Table 4) . Moreover, the total duration of endocrine therapies after relapse was significantly longer in patients with a duration of the first-line endocrine therapy[6 months (p \ 0.0001). Mean total duration of endocrine therapies after relapse was 32.7 months in patients that were treated with the firstline endocrine therapy for [6 months, while it was 12.0 months in those with a duration of B6 months (Table 4 ). Other clinicopathological factors and treatments were similar, in patients with the late recurrence independently of the duration of the first-line endocrine therapy.
Discussion
We investigated the clinicopathological factors and treatments predicting post-relapse survival in ER-positive, HER2-negative breast cancer patients with the early and late recurrence. Our results demonstrated that post-relapse survival was significantly longer in patients with the late recurrence than in those with the early recurrence, and that predictors for prognosis after relapse were different between the two cohorts. Predictive factors for post-relapse survival in patients with the early recurrence were the lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine and chemotherapies after relapse. In patients with the late recurrence, the involvement of metastasis in only one organ at relapse, a long duration of first-line endocrine therapy, and a long total duration of endocrine therapies after relapse significantly improved post-relapse survival. Moreover, The ER expression in primary breast tumors of late recurrence patients was significantly higher in patients with a duration of the first-line endocrine therapy [6 months than in those with a duration B6 months. Our previous study demonstrated that predictive factors for the early and late recurrence were mainly a large tumor size and a large number of positive lymph nodes [9] . However, as expected, tumor size and lymph node status at the initial treatments were not associated with post-relapse survival in patients with both the early and late recurrence. Approximately two-thirds of women who relapsed within 5 years had received anthracyclines and/or taxanes as adjuvant or neoadjuvant chemotherapy. Moreover, approximately 90 % of patients with the early recurrence developed distant metastasis during adjuvant endocrine therapy. Therefore, we infer that most patients with the early recurrence in our study were resistant to the standard endocrine therapies and chemotherapies. On the other hand, our present study shows that the lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine and chemotherapies after relapse were independent prognostic factors for patients with the early relapse; furthermore, low tumor grade and low Ki67 LI were associated with longer post-relapse survival in the univariate analysis. The 5-year post-relapse survival was significantly longer in patients with a disease-free interval [3 years than in patients with a disease-free interval B3 years. Despite the occurrence of relapse within 5 years of the initial treatments, we suggest that patients with a disease-free interval [3 years have relatively low-grade tumors that essentially remain responsive to other endocrine or chemotherapeutic agents.
Our results further show that single metastatic organ at relapse, a long duration of the first-line endocrine therapy, and a long total duration of endocrine therapies after relapse are independent prognostic factors for post-relapse [18] . Endocrine therapy is usually recommended as the first-line treatment for patients with boneonly metastases in ER-positive breast cancer. Here, we demonstrated that 79 % of patients with the late relapse received endocrine therapy as the first-line treatment after relapse. Moreover, 76 % of patients who received endocrine therapy as the first-line treatment responded to the treatment, such as a duration of the first-line endocrine therapy [6 months. In contrast, 24 % of patients who did not respond to the first-line endocrine therapy had a worse prognosis, as the 5-year post-relapse survival was 41 %; this is similar to the 5-year post-relapse survival in patients with the early recurrence (35 %). Most patients who do not respond to the first-line endocrine therapy after relapse are likely to be endocrine-resistant, and chemotherapies are usually selected as the second-line treatment [19] . Our results show that in patients with the late recurrence, ER expression in primary breast tumors was significantly higher in patients with a duration of the first-line endocrine therapy [6 months than in those treated for shorter periods, whereas other clinicopathological factors were not correlated with response to the first-line endocrine therapy. Although ER expression and endocrine responsiveness in metastatic sites are reduced as the disease progresses [20] , malignancies at the initial metastatic sites may retain the biology of primary breast tumors, despite the lapse of time since the initial treatments [21] . Furthermore, a recent study showed that an epithelial to mesenchymal transition-related gene signature in the primary breast tumors is related stromal activation and escape from disease dormancy [22] .
Recently, the inhibitors of mTOR, CDK 4/6, and PI3K have been developed and used in combination with endocrine therapies in ER-positive metastatic breast cancer [16] . Understanding predictors for the response to endocrine therapy and overall survival in metastatic ER-positive breast cancer will facilitate the stratification of patients to be treated with specific targeted molecular therapies.
In conclusion, our study demonstrates that the predictors of prognosis after relapse are different between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ERpositive, HER2-negative recurrent breast cancer. 
